Human RCTPubMed ID: 28794118·2017
SUSTAIN-5: Semaglutide in Type 2 Diabetes on Background Insulin
Sorli C, Harashima S, Tsoukas GM, et al.
Diabetes Care, 2017 · n = 1037
Key finding
Semaglutide 1.0mg added to insulin reduced HbA1c by 1.2% versus 0.5% placebo (p<0.001), with modest weight loss of 0.9kg despite insulin.
Summary
Phase 3b trial of semaglutide added to basal insulin in type 2 diabetes patients.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Semaglutide
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)
New England Journal of Medicine · 2023 · Human RCT
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
New England Journal of Medicine · 2023 · Human RCT
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine · 2022 · Human RCT
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)
JAMA · 2022 · Human RCT
STEP 3: Semaglutide for Weight Management in Severe Obesity
New England Journal of Medicine · 2022 · Human RCT